NTLA as reported
Intellia Therapeutics, Inc. reported $66M of revenue over the trailing twelve months, +45% on the year before. 9 reported series are charted on this page, each one as filed.
$66M
Revenue, trailing twelve months · to Q1 2026 · +45% against the twelve months before
- Net Income
- −$395M
Net Income · −25% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$364M
Free Cash Flow · −4.6% year on year · trailing twelve months to Q1 2026
- Op Margin
- −669%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $66M | +45% | Q1 2026 |
| Net Income | −$395M | −25% | Q1 2026 |
| EPS | −$3.53 | −32% | Q1 2026 |
| Gross Margin | 100% | n/a | Q4 2019 · 25 quarters behind |
| Op Margin | −669% | n/a | Q1 2026 |
| Net Margin | −625% | n/a | Q1 2026 |
| ROE | −63% | n/a | Q1 2026 |
| ROA | −51% | n/a | Q1 2026 |
| Free Cash Flow | −$364M | −4.6% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Intellia Therapeutics, Inc. (NTLA) - Revenue & ProfitRevenue & ProfitIntellia Therapeutics, Inc. (NTLA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com